These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37661552)

  • 1. Reply to Thomas Seisen, Morgan Rouprêt, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Zlotta AR; Lajkosz K; Efstathiou JA
    Eur Urol; 2024 Jan; 85(1):e25-e26. PubMed ID: 37661552
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Seisen T; Rouprêt M; Blanchard P
    Eur Urol; 2024 Jan; 85(1):e24. PubMed ID: 37659960
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Thomas Seisen, Morgan Rouprêt, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J Clin Oncol 2023;41:4406-15.
    Swinton M; Hoskin P; Choudhury A
    Eur Urol; 2024 Jan; 85(1):e22-e23. PubMed ID: 37865547
    [No Abstract]   [Full Text] [Related]  

  • 4. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28.
    Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF
    Eur Urol; 2019 Apr; 75(4):e98-e99. PubMed ID: 30503180
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Cigliola A; Mercinelli C; Patanè D; Raggi D; Necchi A
    Eur Urol; 2023 Dec; 84(6):602-603. PubMed ID: 37451897
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052-68: The Key Role of Flexible Ureterorenoscopy in Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma.
    Seisen T; Babjuk M; Rouprêt M
    Eur Urol; 2017 Apr; 71(4):e111-e112. PubMed ID: 27666997
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
    Contieri R; Hensley PJ; Kamat AM
    Eur Urol Oncol; 2024 Apr; 7(2):301. PubMed ID: 37806840
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
    Kamran SC; Seisen T; Markt SC; Preston MA; Trinh QD; Frazier LA; Choueiri TK; Martin NE; Nguyen PL; Beard CJ
    Eur Urol; 2018 Apr; 73(4):e96-e97. PubMed ID: 29358058
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Basile G; Bandini M; Montorsi F; Necchi A
    Eur Urol; 2023 Apr; 83(4):e111-e112. PubMed ID: 36707359
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Michael Froehner, Rainer Koch and Manfred P. Wirth's letter to the editor re: Roman Mayr, Matthias May, Thomas Martini, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662-70.
    Mayr R; May M; Fritsche HM
    Eur Urol; 2013 Jan; 63(1):e10. PubMed ID: 23079054
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Rouprêt M
    Eur Urol; 2016 Mar; 69(3):e51-2. PubMed ID: 26461109
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
    Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply letter to: Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018 Nov 1;4(11):1535-1542.
    Boeri L; Montanari E; Karnes RJ
    World J Urol; 2020 May; 38(5):1341-1342. PubMed ID: 30944970
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter to the editor: Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Chen Y; Liao Y; Yang Y; Zheng X
    Int J Surg; 2024 Feb; 110(2):1289-1290. PubMed ID: 38000058
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
    Seisen T; Kamran SC; Markt SC; Preston MA; Trinh QD; Frazier LA; Choueiri TK; Martin NE; Nguyen PL; Beard CJ
    Eur Urol; 2018 Apr; 73(4):e100-e101. PubMed ID: 29108659
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: James W.F. Catto, Pramit Khetrapal, Federico Ricciardi, et al. Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. JAMA 2022;327:2092-103: Lacking the Evidence for Neobladder Use After Radical Cystectomy.
    Catto JWF; Khetrapal P; Ambler G; Williams NR; Brew-Graves C; Kelly JD;
    Eur Urol; 2022 Dec; 82(6):e167-e168. PubMed ID: 36114078
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Emily Vertosick and Andrew Vickers' letter to the editor re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 Prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87.
    Briganti A
    Eur Urol; 2013 Apr; 63(4):e51-2. PubMed ID: 23305881
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer.
    Vetterlein MW; Gild P; Fisch M; Rink M
    Eur Urol; 2020 Aug; 78(2):e77-e78. PubMed ID: 32376138
    [No Abstract]   [Full Text] [Related]  

  • 20. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Johnson SB; Yu JB
    Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.